Table 4.
Recent CAR–NK clinical trials including NK cell receptors in the CAR construct.
| NK Cell Receptor | Product Name | Malignancy | NK Cell Source | Sponsor | Location | Status | Clinical Phase | Year | Key Outcomes | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|---|---|---|---|
| NKG2DL | NKG2D-CAR–NK92 cells | Relapsed/Refractory Solid Tumors | NK-92 | Xinxiang medical university | Xinxiang CHI | Recruiting | I | 2023 | - | NCT05528341 |
| NKG2DL | NKG2D CAR–NK Cell Therapy | Relapsed or Refractory Acute Myeloid Leukemia | Intravenous infusion | Hangzhou Cheetah Cell Therapeutics Co., Ltd. | Sanhe CHI | Terminated | Unknown | 2021 | - | NCT05247957 |
| NKG2DL | CAR–NK cells targeting NKG2D ligands | Metastatic Solid Tumors | PBMCs | The Third Affiliated Hospital of Guangzhou Medical University | Guangzhou CHI | Unknown | I | 2018 | In total, 2 out of 3 patients showed reduced ascites and fewer tumor cells. 1 out of 3 patients experienced rapid tumor regression and complete metabolic liver response. | NCT03415100 |
| NKG2DL | NKG2D CAR–NK | Refractory Metastatic Colorectal Cancer | - | Zhejiang University | Hangzhou CHI | Recruiting | I | 2021 | - | NCT05213195 |
| NKG2DL | NKX101 | Relapsed/Refractory AML and MDS | PB-NK | Nkarta Inc. | Denver CO, Jacksonville FL, Atlanta GA USA | Active, not recruiting | I | 2020 | Initial Outcomes: NKX101 shows encouraging early responses in relapsed/refractory AML, even in high-risk cases. The toxicity profile matches expectations, with no CRS, ICANS, or treatment-related deaths. | NCT04623944 |
| NKG2DL | NKG2D CAR–NK | AML | Unknown | Zhejiang University | Hangzhou CHI | Recruiting | Unknown | 2023 | - | NCT05734898 |
| NKG2DL | NKG2D CAR–NK | Ovarian Cancer | Unknown | Hangzhou Cheetah Cell Therapeutics Co., Ltd. | Hangzhou CHI | Recruiting | NA | 2023 | - | NCT05776355 |
| NKG2DL and PD-L1 | PD-1/NKG2D CAR–NK | Non-small Cell Lung Carcinoma | NK-92 | Xinxiang medical university | Xinxiang CHI | Completed | I | 2018 | A previously unreported instance of cytokine release syndrome (CRS) occurred, marking the first known case during CAR–NK therapy | NCT03656705 |
| PD-L1 | PD-L1 CAR–NK, Pembrolizumab, N-803 | Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC | t-haNK | National Cancer Institute (NCI) | Bethesda MD USA | Recruiting | II | 2021 | - | NCT04847466 |